tbuckley/cabot-search huggingface dataset:
Thoracic Epidural Anesthesia Reduces Right Ventricular Systolic Function With Maintained Ventricular-Pulmonary Coupling
Authors: Jeroen Wink, Rob B. P. de Wilde, Patrick F. Wouters, Eveline L. A. van Dorp, Bernadette Th. Veering, Michel I. M. Versteegh, Leon P. H. J. Aarts, Paul Steendijk
Journal: Circulation (2016)

Blockade of cardiac sympathetic fibers by thoracic epidural anesthesia may affect right ventricular function and interfere with the coupling between right ventricular function and right ventricular afterload. Our main objectives were to study the effects of thoracic epidural anesthesia on right ventricular function and ventricular-pulmonary coupling.In 10 patients scheduled for lung resection, right ventricular function and its response to increased afterload, induced by temporary, unilateral clamping of the pulmonary artery, was tested before and after induction of thoracic epidural anesthesia using combined pressure-conductance catheters.Thoracic epidural anesthesia resulted in a significant decrease in right ventricular contractility (ΔESV25: +25.5 mL, P=0.0003; ΔEes: -0.025 mm Hg/mL, P=0.04). Stroke work, dP/dtMAX, and ejection fraction showed a similar decrease in systolic function (all P<0.05). A concomitant decrease in effective arterial elastance (ΔEa: -0.094 mm Hg/mL, P=0.004) yielded unchanged ventricular-pulmonary coupling. Cardiac output, systemic vascular resistance, and mean arterial blood pressure were unchanged. Clamping of the pulmonary artery significantly increased afterload (ΔEa: +0.226 mm Hg/mL, P<0.001). In response, right ventricular contractility increased (ΔESV25: -26.6 mL, P=0.0002; ΔEes: +0.034 mm Hg/mL, P=0.008), but ventricular-pulmonary coupling decreased (Δ(Ees/Ea) = -0.153, P<0.0001). None of the measured indices showed significant interactive effects, indicating that the effects of increased afterload were the same before and after thoracic epidural anesthesia.Thoracic epidural anesthesia impairs right ventricular contractility but does not inhibit the native positive inotropic response of the right ventricle to increased afterload. Right ventricular-pulmonary arterial coupling was decreased with increased afterload but not affected by the induction of thoracic epidural anesthesia.URL: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=2844. Unique identifier: NTR2844.
Dual-Tracer PET/CT Using 18F-FDG and 11C-Acetate in Gastric Adenocarcinoma With Liver Metastasis
Authors: Varut Vardhanabhuti, Anthony W.I. Lo, Elaine Y.P. Lee, Simon Y.K. Law
Journal: Clinical Nuclear Medicine (2016)

Dual-tracer F-FDG and C-acetate PET/CT has been shown to demonstrate good sensitivity and specificity for the diagnosis of hepatocellular carcinoma. We present a case of gastric adenocarcinoma with liver metastasis with positive uptake of F-FDG and C-acetate highlighting an unusual appearance in dual-tracer PET/CT.
Second-generation EGFR-TKI (afatinib) rechallenge to overcome acquired resistance to first-generation EGFR-TKIs
Authors: Takayuki Takeda, Hideki Itano, Masahiko Saitoh, Noriyuki Kohno, Takahiro Takemoto, Kuniaki Hirata, Toshiki Tanaka, Sorou Takeda
Journal: Annals of Oncology (2015)
B7-04: Detection of EGFR mutations in plasma by allele-specific real-time PCR in non-small cell lung cancer (NSCLC)
Authors: Philip C. Mack, William S. Holland, Angela M. Davies, Nichole C. Farneth, Oliver Gautschi, Primo N. Lara, David R. Gandara
Journal: Journal of Thoracic Oncology (2007)
Norepinephrine Transporter in Major Depressive Disorder: A PET Study
Authors: Sho Moriguchi, Makiko Yamada, Harumasa Takano, Tomohisa Nagashima, Keisuke Takahata, Keita Yokokawa, Takehito Ito, Tatsuya Ishii, Yasuyuki Kimura, Ming-Rong Zhang, Masaru Mimura, Tetsuya Suhara
Journal: American Journal of Psychiatry (2016)

The norepinephrine transporter has been suggested to play a crucial role in major depressive disorder. However, norepinephrine transporter availability in major depressive disorder and its role with clinical symptoms are not known. The authors tested norepinephrine transporter availability in patients with major depressive disorder with the aim to identify any associations between test results and clinical symptoms.The present research was a cross-sectional study in which 19 patients with major depressive disorder and 19 age- and sex-matched healthy comparison subjects underwent positron emission tomography scanning to evaluate the norepinephrine transporter availability measured by the radioligand (S,S)-[18F]FMeNER-D2. Norepinephrine transporter availability in the thalamus and its subregions was quantified in terms of nondisplaceable binding potential (BPND). The authors also analyzed the association between norepinephrine transporter availability and clinical symptoms.Compared with healthy subjects, patients with major depressive disorder showed 29.0% higher BPND values in the thalamus and, in particular, 28.2% higher values in the thalamic subregion anatomically connected to the prefrontal cortex. Elevated norepinephrine transporter availability in the thalamus in patients was positively correlated with attention, as measured by the Trail Making Test, part A.These findings revealed altered norepinephrine transmission in patients with major depressive disorder, suggesting that this alteration could be related to attention in this patient population.
P2-033: Polymorphisms of Jak3 contribute to diminished promoter activity and increased risk of lung cancer in Korea populations
Authors: Won-Beak Yoo, Sle Gi Lo Han, Uk Hyun Jo, Jun Seok Jung, Hyo Seon Choi, Jae Suk Sung, Jun Suk Kim, Yeul Hong Kim
Journal: Journal of Thoracic Oncology (2007)
Epidémiologie des infections à Mycoplasma pneumoniae en Pologne : 28 années de surveillance à Varsovie, 1970-1997
Authors: W Rastawicki, S Kaluzewski, M Jagielski, R Gierczyski
Journal: Eurosurveillance (1998)

Mycoplasma pneumoniae est une cause frequente d’infections des voies respiratoires inferieures chez l’homme, en particulier chez les enfants, les adolescents et les jeunes adultes. Ces infections sont endemiques dans les villes et une periodicite de 4 a 7 ans a ete observee dans la survenue d’epidemies. L’infection a M. pneumoniae evolue lentement et sa culture est difficile et lente. La serologie est donc le procede le plus souvent utilise pour diagnostiquer les infections a M. pneumoniae, notamment par le test de fixation du complement (TFC) (1,2).
Current physical activity guidance is misinterpreted
Authors: Liaquat R Johnson
Journal: BMJ (2016)

It’s heartening to see the dose-response effect of physical activity on the risk of developing breast cancer, colon cancer, diabetes, ischaemic heart disease, and ischaemic stroke events.1

WHO has identified physical inactivity as one of four major risk factors for developing non-communicable diseases.2 But it also reports that, at the global level, one in four adults is insufficiently physically …
Image Gallery: Eruptive disseminated lentiginous Spitz naevi
Authors: N. Scheiba, W. Hartschuh
Journal: British Journal of Dermatology (2016)

Funding sources: none. Conflicts of interest: none declared. Dear Editor, The pictures show the exceptional case of a 17‐year‐old male patient who developed multiple pinpoint‐like, heavily pigmented lentiginous moles on his face, neck, clavicle and arms within a period of several months. No triggers could be determined. Histological examinations of six moles confirmed junctional Spitz naevi, all of which showed a uniform pattern. The patient was otherwise healthy and the family history was unremarkable, especially concerning hereditary disorders, Spitz naevi or malignant melanoma. Disseminated, eruptive Spitz naevi are very rare (original magnification X 10).1 2 The underlying genetic disorders are unknown. Further genetic analyses are planned to reveal a closer insight into the development of melanocytic neoplasms. We thank Professor B. Bastian (San Francisco, CA, U.S.A.) for initiating further genetic analyses of the described Spitz naevi.
Regional myocardial nitric oxide synthase 3 gene transfer reduces tissue-specific consequences of anti adenoviral immune response
Authors: Z Szelid, Peter Sinnaeve, H Gillijns, Marijke Pellens, veerle Laurysens, N Van Pelt, Pieter Vermeersch, AJ Van Zonneveld, Eric Verbeken, Desire Collen, Stefan Janssens
Journal: Journal of the American College of Cardiology (2001)
Cis-Regulatory Evolution of Forkhead Box O1 (FOXO1), a Terminal Selector Gene for Decidual Stromal Cell Identity
Authors: Yeonwoo Park, Mauris C. Nnamani, Jamie Maziarz, Günter P. Wagner
Journal: Molecular Biology and Evolution (2016)

Studies in human and mouse have shown that decidual stromal cells (DSC), which develop in the innermost lining of uterus, mediate placentation by regulating maternal immune response against the fetus and the extent of fetal invasion. Investigating when and how DSC evolved is thus a key step to reconstructing the evolutionary history of mammalian pregnancy. We present molecular evidence placing the origin of DSC in the stem lineage of eutherians (extant placental mammals). The transcription factor forkhead box O1 (FOXO1) is a part of the core regulatory transcription factor complex (CoRC) that establishes the cell type identity of DSC. Decidualization, the process through which DSC differentiate from endometrial stromal fibroblasts, requires transcriptional upregulation of FOXO1. Contrary to other examples in mammals where gene recruitment is caused by the origin of an alternative promoter, FOXO1 is transcribed from the same promoter in DSC as in endometrial stromal fibroblasts. Comparing the activities of FOXO1 promoters from human, mouse, manatee (Afrotheria), and opossum (marsupial) revealed that FOXO1 promoter evolved responsiveness to decidualization signals in the stem lineage of eutherians. This eutherian vs. marsupial pattern of promoter activity was not observed in some other cell types expressing FOXO1, suggesting that this cis-regulatory evolution occurred specifically in the context of the origin of DSC. Sequence comparison revealed eutherian-specifically conserved nucleotides that contribute to the eutherian promoter activity. We conclude that the cis-regulatory activity of a terminal selector gene for decidual stromal cell identity evolved in the stem lineage of eutherians supporting a model where decidual cells are a eutherian innovation.
Early CD4+ T-Cell Effector Alloreactivity Towards Multiple Mismatched HLA Class II Alleles Is Associated with Graft Predominance after Double Umbilical Cord Blood Transplantation (dUCBT)
Authors: Jan J. Cornelissen, Rebecca Wijers, Cornelis A.M. van Bergen, Judith Somers, Eric Braakman, Jan W. Gratama, Reno Debets, J.H. Frederik Falkenburg, Cor Lamers
Journal: Blood (2015)
Prolyl hydroxylase domain 1 (PHD1) to mediate chemoresistance in colorectal cancer.
Authors: Hans Prenen, Sofie Deschoemaeker, Giusy Di Conza, Rosa Martin-Perez, Massimiliano Mazzone
Journal: Journal of Clinical Oncology (2015)

e14534 Background: Chemotherapy is the standard palliative treatment to increase survival of metastatic colorectal cancer (mCRC) patients. Albeit chemotherapy is often capable of inducing cell death, most mCRC patients die because of treatment failure. The prolyl hydroxylase domain proteins (PHD) are oxygen sensors known to target the hypoxia-inducible transcriptional factors HIF-1α and HIF-2α, leading to its degradation. In CRC, PHD2 and PHD3 have been suggested to act as tumor suppressors while the role of PHD1 is not clear. The transcription factor p53 is the most characterized cell stress sensor and tumor suppressor. We investigated if and how PHD1 and p53 are intertwined in colorectal cancer cells during stress responses such as treatment with chemotherapy. Methods: Different CRC cell lines (HCT116, p53-/- HCT116 and p53R248/-HCT116, LIM1215) were used to explore the effect of PHD1 silencing on sensitivity to chemotherapeutic agents such as 5-FU, oxaliplatin and irinotecan. Results: We show in vitro that expression of PHD1, but not PHD2 and 3, can cause resistance to chemotherapy treatment due to a p53-mediated increase in DNA repair. As a consequence, genetic inhibition of PHD1 in vitro can increase the sensitivity of colorectal cancer cells towards chemotherapy. These results were confirmed in vivo in a subcutaneous model of colorectal cancer where PHD1 is genetically silenced in combination with 5-FU treatment and showed a reduction in tumor growth upon 5-FU treatment in combination with PHD1 blockage comparing to 5-FU treatment alone. Conclusions: These data provide evidence that PHD1 is part of a resistance mechanism in CRC cells to chemotherapy, paving the way to drug design of PHD1 specific inhibitors to be used in combination with chemotherapy.
Abstract P5-05-05: Computational modeling of breast cancer growth and spread: the role of matrix degrading enzymes
Authors: NE Deakin, AM Thompson, MAJ Chaplain
Journal: Cancer Research (2012)

Abstract Background: A “hallmark” of cancer growth and metastatic spread is the process of local invasion of the surrounding tissue. Cancer cells achieve this by the secretion of enzymes involved in proteolysis (tissue degradation) including matrix metalloproteinases (MMPs). These over-expressed proteolytic enzymes then proceed to degrade the host tissue allowing the cancer cells to disseminate throughout the microenvironment by active migration and interaction with components of the extracellular matrix such as collagen. The implications of MMP-2 activation by MMP-14 and the tissue inhibitor of metalloproteinases-2 (TIMP2) can be considered alongside the suitability of the matrix to be invaded. The suitability of the matrix incorporates pore size, since in some highly dense collagen structures such as breast tissue, the cancer cells are unable to physically fit through a porous region and rely on membrane-bound MMPs to forge a path through which degradation by other MMPs and movement of cancer cells can occur. Method: We have developed a multi-scale mathematical model of breast cancer cell invasion of host tissue by combining both micro- (cell) and macro- (tissue) scale dynamics. The model considers cancer cells and two matrix-degrading enzymes from the MMP family of differing mechanistic actions, namely MMP-2 and the membrane bound MMP-14 (also called MT1-MMP), and their interaction with, and effect on, the extracellular matrix (ECM) in a 2-D spatial domain. For the macro-scale we use a system of reaction-diffusion-taxis partial differential equations to capture the qualitative dynamics of the migratory response of the cancer cells. The micro-scale operates over a smaller spatial and temporal scale, and as such allows us to explicitly examine the stochastic role which is inherent within the region of enzyme operation. Computational simulations of the equations predict the spatio-temporal evolution of the cancer cell density, the concentration levels of the various enzymes and the density of the extracellular matrix. Results: The model exhibits a rich range of dynamic and heterogeneous spatio-temporal solutions, which qualitatively match experimental and clinically observed results for aggressive breast carcinoma invasion and can be used to determine the speed of invasion through a variety of structured mediums such as the highly dense collagen constitution of some peritumoral stroma. Using the “worst case” scenario, an estimate for the maximum region of invasion over time from the initial data can be obtained suggesting the likely extent of breast cancer cell invasion into the surrounding tissue. Conclusion: This modeling is most relevant to and informs the biological processes occurring in early stage breast cancer, in which local invasion is a crucial aspect of tumor behavior. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-05-05.
Over the Steep Rise
Authors: Kevin Hadduck
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pharmaceutical Industry Interactions With Nonprescribing Clinicians
Authors: Elissa Ladd, Alex Hoyt
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
MAGRIT phase III trial in adjuvant NSCLC: MAGE-A3 gene expression frequency on the first 2150 patients screened and demographics of first patients randomized
Authors: Tommaso De Pas, Joo-Hang Kim, Konstantinos Zarogoulidis, Marcin Zielinski, Jubrail Dahabreh, Tonu Vanakesa, Arnd Nush, Emilio Esteban Gonzalez, Hans Hoffman, Sumitra Thongprasert, Muriel Debois, Jean-Yves Douillard, Nasser Altorki, Channa Debruyne, Johan Vansteenkiste
Journal: Journal of Thoracic Oncology (2009)
Final results from randomized phase II trial of preoperative docetaxel (D) and capecitabine (C) given sequentially or concurrently for HER2-negative breast cancers.
Authors: A. B. Zelnak, S. Harichand-Herdt, T. M. Styblo, M. Rizzo, S. G. A. Gabram, H. L. Bumpers, R. C. Hermann, J. Srinivasiah, F. M. Schnell, R. O'Regan
Journal: Journal of Clinical Oncology (2011)

1118 Background: Achievement of pathologic complete response (pCR) to preoperative therapy is a predictor of improved disease-free and overall survival. Sequential and concurrent regimens of D and C were evaluated in patients with Her2-negative breast cancers who were candidates for preoperative chemotherapy. Methods: Patients with Stage I (>1.0 cm), II or III, Her-negative breast cancer from Georgia-based oncology network were randomized between Arm A: sequential therapy with D 100 mg/m2 every 3 weeks for 4 cycles followed by C 1000 mg/m2 PO BID on days 1-14 of 3 week cycle for 4 cycles; Arm B: concurrent therapy with with D 50 mg/m2 on day 1 and C 1000 mg/m2 PO BID on days 1-7 of 2 week cycle for 8 cycles. Primary endpoint was pCR rate; secondary endpoints included response rate and toxicity. Results: 51 patients were accrued (4/2007–7/2009), Arm A (n=25) Arm B (n=26) and are evaluable for primary endpoint. Patients were accrued at academic center (45%), county hospital (33%), and community sites (22%). Median age was 50.3 years. Median tumor size was 6.1 cm. 35 of 51 (68.6%) were clinically node-positive at study entry. 57% of patients were African American, 35% Caucasian, and 8% other. 30 of 51 (58.8%) of patients had ER and/or PR-positive tumors; 21 of 51 (41.2%) had ER/PR-negative tumors (triple negative). Treatment was well-tolerated with expected grade 3-4 toxicities: neutropenia 15.7%; hand-foot syndrome 5.9%; neuropathy 3.9%. On Arm A, clinical complete response (CR) rate was 32%. Partial response (PR) rate was 28%. Stable disease (SD) rate was 12 %. Progressive disease (PD) rate was 28%. On Arm B, clinical CR rate was 46.2%. PR rate was 42.3%. SD rate was 3.8%. PD rate was 7.7%. pCR rate was 8% for Arm A and 11.5% for Arm B. Among triple negative breast cancer subjects, pCR rate was 19%. Conclusions: This is the first clinical trial to accrue patients through a Georgia-based oncology trial network and more than half of enrolled patients were African American. The final results from this phase II trial of D and C show that both regimens were well-tolerated and had modest clinical activity, with greater activity in the concurrent therapy arm and among triple negative patients.
Anti-Neoplastic Effect Of High Affinity and Covalent-Binding Microtubule Stabilizing Agents In AML Cells Sensitive and Resistant By ABC-Transporter Overexpression
Authors: Benet Pera, Michel Jordi, Ruben Hoya-Arias, José Fernando Díaz, Weishuo Fang, Karl-Heinz Altmann, Malcolm A.S. Moore
Journal: Blood (2013)
P3-276: Limited resection trial for pulmonary ground-glass opacity nodules: case selection based on high resolution computed tomography
Authors: Junji Yoshida, Genichiro Ishii, Kanji Nagai, Mitsuyo Nishimura, Hiroyuki Ito, Yoichi Kameda, Haruhiko Nakayama, Kouzou Yamada, Yutaka Nishiwaki
Journal: Journal of Thoracic Oncology (2007)
Thrombopoietin Receptor Agonist (TPO-RA) Switch in Adult Primary Immune Thrombocytopenia (ITP) Patients: A Retrospective Collaborative Survey from 8 Italian Hematology Centers
Authors: Silvia Cantoni, Monica Carpenedo, Maria Gabriella Mazzucconi, Valerio De Stefano, Marco Ruggeri, Nicola Vianelli, Francesco Zaja, Wilma Barcellini, Michele Nichelatti, Veronica Coccini, Erminia Baldacci, Elena Rossi, Simona Puglisi, Angela Ciminello, Roberto Cairoli
Journal: Blood (2015)
P2-041: Epigenetic changes of the tumor suppressor genes SHP1, SHP2 SOCS1, SOCS3 and the transcription factor STAT1 in human lung cancer
Authors: Joachim Gullbo, Michael Bergqvist, Linda Sooman, Peter Ericsson, Johan Lennartsson, Daniel Brattström, Stefan Bergström, Simon Ekman
Journal: Journal of Thoracic Oncology (2007)
Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation
Authors: Kei E Fujimura, Alexandra R Sitarik, Suzanne Havstad, Din L Lin, Sophia Levan, Douglas Fadrosh, Ariane R Panzer, Brandon LaMere, Elze Rackaityte, Nicholas W Lukacs, Ganesa Wegienka, Homer A Boushey, Dennis R Ownby, Edward M Zoratti, Albert M Levin, Christine C Johnson, Susan V Lynch
Journal: Nature Medicine (2016)